Abbott (ABT) Receives Outperform Rating Amid Positive Q2 Results
Related Stocks: ABT
Read the full articleYou might also wanna read
Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
Abbott's Q2 results show solid organic growth, better-than-expected margins, and improved earnings guidance, easing concerns over the Exact
Abbott Laboratories NYSE:ABT Rises on In-Line Q2 and Raised Guidance
Abbott Labs Q2 2026 earnings met expectations, slightly beating EPS estimates. The company raised its full-year guidance, boosting investor
Dividend Powerhouse: Abbott Laboratories (NYSE:ABT) Passes the Test for Sustainable Income
Abbott Laboratories offers a reliable 2.64% dividend yield backed by strong profitability, a 10-year growth history, and a reasonable P/E ra
Health stocks today: Abbott (NYSE: ABT) jumps 11% as insurers split
NEW YORK, July 16, 2026, 14:23 (EDT). U.S. markets open. The Health Care Select Sector SPDR Fund (NYSEARCA: XLV) rose 2.2% to $161.81. The S
Abbott raises 2026 profit forecast on strength in diagnostics, heart devices
Abbott’s quarterly sales in its medical devices segment grew 9% to US$5.85 billion
What Investors Don’t Understand About Abbott Laboratories
Wall Street still prices Abbott like a slow-and-steady dividend stalwart, but a pair of massive strategic moves beneath the surface suggests
Comments
Sign in to join the conversation.
No comments yet. Be the first.